AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 62 min read$NTRA

Chapman Steven Leonard sold $819K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 3,076 shares of Natera, Inc. (NTRA) at an average of $266.40 ($259.98–$268.22, $0.82M total) across 7 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Aug 6, 2026, 1:35 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure updates the record of insider activity, but the pre-arranged 10b5-1 structure reduces the likelihood of a new fundamental narrative.

02

Market read

Traders may monitor insider activity for sentiment, but this specific filing is unlikely to drive a durable repricing without additional company news.

03

What to watch

The article does not state whether the CEO increased other holdings, sold for tax/option exercises, or whether there were concurrent company-specific catalysts; without that, the trading signal is weak.

Relevance 4/10Novelty 4/10Timing: filed Aug 5, covering sales executed Aug 3

Background

This is an SEC Form 4 insider transaction for Natera, Inc., reported by the CEO and President.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO and President Chapman Steven Leonard sold about $819K of NTRA shares via an open-market sale under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 shows a scheduled 10b5-1 sale (not a surprise discretionary sale) and provides no accompanying operational or guidance change.

Market effects

Sector

Minimal; insider selling in a single biotech/diagnostics name does not reset sector fundamentals.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations, so any negative read-through could be overdone.

Key entities

  • issuer
    Natera, Inc.

    Company whose CEO and President reported an open-market sale of shares on a 10b5-1 plan.

  • insider
    Chapman Steven Leonard

    CEO and President who sold 3,076 shares across seven trades on Aug 3, 2026.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

AUG 24
$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

fool.com2 min
AUG 14
$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

fool.com6 min
AUG 7
$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min